Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
CaPre
Grace Therapeutics
Hypertriglyceridemia
2 trials -
Cadisegliatin 800 mg QD
vTv Therapeutics
Diabetes Mellitus, Type 1
1 trial -
Candesartan and standard chronic heart disease therapy
Takeda
Heart Failure
1 trial -
Cannabidiol, pharmaceutically produced with < 5 ppm THC
Cardiol Therapeutics
COVID-19
1 trial -
Capecitabine monotherapy
The First People's Hospital of Lianyungang
Gastric Cancer
1 trial -
Capivasertib, Faslodex 250 mg solution for injection., Placebo to Capivasertib, Capivasertib
AstraZeneca AB
Locally advanced (inoperable) or metastatic HR+/HER2 breast cancer
1 trial -
Capox chemotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Rectal Cancer
1 trial -
Carbetocin
United Therapeutics Europe Ltd
Post Partum Haemorrhage
1 trial -
Carboplatin
Alaunos Therapeutics
Extensive-Stage Small Cell Lung Cancer
1 trial -
Carboplatin
United Therapeutics Europe Ltd
Breast Cancer
1 trial -
CardiolRx
Cardiol Therapeutics
Recurrent Pericarditis
2 trials -
CardiolRx™ Placebo is a non-aqueous solution of medium chain triglycerides with 1.0% vitamin E as anti-oxidant. CardiolRx™ Placebo is a pale yellow clear liquid. The CardiolRx™ Placebo product is essentially the same as the CardiolRx™ drug product with the exception that the placebo does not include the active drug substance, cannabidiol., CardiolRx
Cardiol Therapeutics
Recurrent Pericarditis
1 trial -
Carraguard (PC-515)
United Therapeutics Europe Ltd
HIV Infections
2 trials -
Casimersen
Sarepta Therapeutics
Duchenne Muscular Dystrophy
1 trial -
Celecoxib
United Therapeutics Europe Ltd
Breast Cancer
1 trial -
Cellulose Sulfate gel (6%)
United Therapeutics Europe Ltd
HIV Infection
1 trial -
Cenerimod 4 mg, Cenerimod matching placebo
Viatris Pharmaceuticals Co.,
Moderate to severe systemic lupus erythematosus
1 trial -
Cenerimod matching placebo, Cenerimod 4 mg
Viatris Pharmaceuticals Co.,
Moderate to severe systemic lupus erythematosus
1 trial -
Chemotherapy
The First People's Hospital of Lianyungang
Endometrial Cancer
1 trial -
Chemotherapy
United Therapeutics Europe Ltd
Transitional Cell Carcinoma of Ureter
1 trial -
Chemotherapy
International Peace Maternity and Child Health Hospital
Non Small Cell Lung Cancer
1 trial -
Chemotherapy
The First People's Hospital of Lianyungang
Acute Lymphoblastic Leukemia
1 trial -
Chemotherapy
Sun Yat-sen University
Nasopharyngeal Carcinoma
1 trial -
Chemotherapy + avelumab followed by avelumab + talazoparib
Pfizer
Ovarian Cancer
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources